Literature DB >> 21905023

Human tumor-induced and naturally occurring Treg cells differentially affect NK cells activated by either IL-2 or target cells.

Christoph Bergmann1, Clarissa A Wild, Mustafa Narwan, Ramin Lotfi, Stephan Lang, Sven Brandau.   

Abstract

NK cells play a crucial role in the eradication of tumor cells. Naturally occurring (n) Treg cells and induced (i) Treg cells are two distinct Treg subsets. While the interaction of nTreg cells with NK cells has been investigated in the past, the role of tumor iTreg cells in the modulation of NK-cell function remains unclear. Tumor iTreg cells were generated from CD4(+) CD25(-) T cells in the presence of autologous immature DCs, head and neck cancer cells and IL-2, IL-10, and IL-15. The effect of iTreg cells and nTreg cells on the expression of NKG2D, NKp44, CD107a, and IFN-γ by NK cells, as well as NK tumor-cytolytic activity, were investigated. iTreg cells - similar to recombinant TGF-β and nTreg cells - inhibited IL-2-induced activation of NK cells in the absence of target cell contact. Surprisingly, and in contrast to nTreg cells, iTreg cells enhanced NK-cell activity elicited by target cell contact. The cytolytic activity of NK cells activated by iTreg cells was mediated via perforin and FasL. We conclude that tumor iTreg cells inhibited IL-2-mediated NK-cell activity in the absence of target cells, whereas the tumoricidal activity of NK cells was enhanced by iTreg cells. Our data suggest a complex, previously not recognized, differential regulation of human NK activity by iTreg cells in the tumor microenvironment.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21905023     DOI: 10.1002/eji.201141532

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  20 in total

1.  Association of peripheral NK cell counts with Helios+ IFN-γ- Tregs in patients with good long-term renal allograft function.

Authors:  K Trojan; L Zhu; M Aly; R Weimer; N Bulut; C Morath; G Opelz; V Daniel
Journal:  Clin Exp Immunol       Date:  2017-03-13       Impact factor: 4.330

2.  Low-dose IL-2 induces CD56bright NK regulation of T cells via NKp44 and NKp46.

Authors:  S T Loughran; P A Power; S L McQuaid; P Maguire; A Szczygiel; P A Johnson
Journal:  Clin Exp Immunol       Date:  2020-02-13       Impact factor: 4.330

Review 3.  Impact of dietary components on NK and Treg cell function for cancer prevention.

Authors:  Young S Kim; Thomas J Sayers; Nancy H Colburn; John A Milner; Howard A Young
Journal:  Mol Carcinog       Date:  2015-04-01       Impact factor: 4.784

Review 4.  Interaction between natural killer cells and regulatory T cells: perspectives for immunotherapy.

Authors:  Isabela Pedroza-Pacheco; Alejandro Madrigal; Aurore Saudemont
Journal:  Cell Mol Immunol       Date:  2013-03-25       Impact factor: 11.530

Review 5.  Natural killer cells and regulatory T cells: how to manipulate a graft for optimal GVL.

Authors:  Michael R Verneris
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

6.  Inflammatory immune responses in tumor microenvironment and metastasis of hepatocellular carcinoma.

Authors:  Lun-Xiu Qin
Journal:  Cancer Microenviron       Date:  2012-06-08

Review 7.  Immunology of hepatocellular carcinoma.

Authors:  Meenakshi Sachdeva; Yogesh K Chawla; Sunil K Arora
Journal:  World J Hepatol       Date:  2015-08-18

8.  [Regulatory T cells and NK cells in cancer patients].

Authors:  C Bergmann
Journal:  HNO       Date:  2014-06       Impact factor: 1.284

Review 9.  NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma.

Authors:  Cheng Sun; Haoyu Sun; Cai Zhang; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2014-10-13       Impact factor: 11.530

10.  Essential role of NK cells in IgG therapy for experimental autoimmune encephalomyelitis.

Authors:  Wai Po Chong; Man To Ling; Yinping Liu; Rachel R Caspi; Wai Man Wong; Wutian Wu; Wenwei Tu; Yu Lung Lau
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.